Sex-specific epidemiological and clinical characteristics of Covid-19 patients in the southeast region of Bangladesh

Md. Aminul Islam^{a,1}, Abdullah Al Marzan^b, Md. Sydul Islam^{c,1}, Samina Sultana^d, Md. Iftakhar Parvej^e, Mohammad Salim Hossain^f, Mohammad Tohid Amin^f, Farzana Ehetasum Hossain^a, Md Abdul Barek^f, Md. Shafiul Hossen^f, Md. Shariful Islam^a, Foysal Hossen^a, Newaz Mohammed Bahadur^c, Md. Shahadat Hossain^g, Nazratun Nayeem Choudhury^h, Md. Didar-ul Alamⁱ, Firoz Ahmed^{a,*}

^aDepartment of Microbiology, Noakhali Science and Technology University, Noakhali-3814, Bangladesh

^bDepartment of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet-3114, Bangladesh

[°]Department of Applied Chemistry and Chemical Engineering, Noakhali Science and Technology University, Noakhali-3814, Bangladesh

^dDepartment of Obstetrics & Gynaecology, President Abdul Hamid Medical College, Karimganj, Kishoreganj-2310, Bangladesh

^eDepartment of Statistics, Noakhali Science and Technology University, Noakhali-3814, Bangladesh

^fDepartment of Pharmacy, Noakhali Science and Technology University, Noakhali-3814, Bangladesh

^gDepartment of Biotechnology and Genetic Engineering, Noakhali Science and Technology University, Noakhali-3814, Bangladesh

^hCentre for Health, Population and Development, Independent University Bangladesh, Dhaka 1212, Bangladesh

ⁱProfessor and Honorable Vice-Chancellor, Noakhali Science and Technology University, Noakhali-3814, Bangladesh

¹These authors contributed equally to this work as first authors.

*Corresponding Author:	Firoz Ahmed, PhD
	Professor and Chairman & Focal Point
	COVID-19 Diagnostic Lab, Department of Microbiology, Noakhali
	Science and Technology University, Noakhali-3814, Bangladesh
	Email: <u>firoz@nstu.edu.bd;</u> <u>firoz19701016@gmail.com</u>
	Mobile: +8801713195658

1	Abstract
2	Background: COVID-19 has become a global pandemic with a high growth rate of confirmed
3	cases. In Bangladesh, both mortality and affected rates are increasing at an alarming rate.
4	Therefore, more comprehensive studies of the epidemiological and clinical characteristics of
5	COVID-19 are required to control this pandemic.
6	Purpose: The present study aimed to compare and analyze the sex-specific epidemiological,
7	clinical characteristics, comorbidities, and other information of confirmed COVID-19 patients
8	from the southeast region in Bangladesh for the first time.
9	Methods: 385 lab-confirmed cases were studied out of 2,471 tested samples between 5 June and
10	10 September 2020. RT-PCR was used for COVID-19 identification and SPSS (version 25) for
11	statistical data analysis.
12	Results: We found that male patients were roughly affected compared to females patients (male
13	74.30% vs. female 25.7%) with an average age of 34.86 ± 15.442 years, and B (+ve) blood group
14	has been identified as a high-risk factor for COVID-19 infection. Workplace, local market, and
15	bank were signified as sex-specific risk zone ($p < 0.001$). Pre-existing medical conditions such as
16	diabetes, hypertension, cardiovascular and respiratory diseases were identified among the
17	patients. Less than half of the confirmed COVID-19 cases in the southeast region were
18	asymptomatic (37.73%) and more prevalent among females than males (male vs. female: 36.84%
19	vs. 40.51%, <i>p</i> = 0.001).
20	Conclusions: The findings may help health authorities and the government take necessary steps
21	for identification and isolation, treatment, prevention, and control of this global pandemic.
22	Keywords: COVID-19, Coronavirus disease, Epidemiological, Clinical features, Asymptomatic,

23 Comorbidities

24 **1 Introduction**

COVID-19 (Coronavirus disease-2019) was first identified in December 2019 in a person at a 25 seafood market in Wuhan city, in Hubei province, China (Chan et al., 2020). It is caused by an 26 unknown pathogenic virus, and somedays later, scientists isolated this new virus from the lower 27 respiratory tract of patients. This virus is a new type of Beta coronavirus, corresponds to a 28 comparatively noted Coronaviridae family, and is identical to Bat SARS-type coronavirus 29 (having 88% identity) and have identity nucleotide with the actual severe acute respiratory 30 31 syndrome (SARS) (80%) and Middle East respiratory syndrome coronavirus (MERS-CoV) (about 50%) epidemic virus (Zheng, 2020). The pathogen of this disease has been confirmed by 32 molecular methods as a new coronavirus and was primarily named a 2019 novel coronavirus 33 34 (2019-nCoV). World Health Organization (WHO) declared the COVID-19 outbreak as the sixth public health emergency of international concern on 30 January 2020 and declared a fresh name, 35 36 called Corona Virus Disease (COVID-19) on 11 February 2020, for the pandemic disease: 37 Corona Virus Disease (COVID-19) (Lai et al., 2020). 38

On the grounds of taxonomy, phylogeny, and developed practice, the International Committee on 39 Taxonomy of Viruses (ICTV) announced the official name of this coronavirus as severe acute 40 41 respiratory syndrome coronavirus 2 (SARS-CoV-2) on 12 February 2020 (Lai et al., 2020). Since the disease's occurrence, it is become a global threat and spreading quickly to provinces in China 42 and more than 210 countries, including Bangladesh, worldwide (Worldometers, n.d.). By 2 43 January 2020, 41 lab-confirmed COVID-19 patients had been detected from hospitals, and less 44 than 50% of them had the implicit illness, including high blood pressure, hyperglycemia, and 45 cardiovascular diseases (C. Huang et al., 2020). As of 22 January 2020, there were 571 registered 46

47	cases of 2019-new coronaviruses (COVID-19) in 25 provinces in China and 17 deaths (Lu,
48	2020). Now, 4636 patients died up to 22 July 2021 in China (Worldometers, n.d.).
49	
50	COVID-19 infects more than 19.3 million patients, and about 4,147,24 (0.22%) died on 22 July
51	2021 worldwide. USA has accounted for the highest number of COVID-19 patients
52	(35,147,918), followed by India (31,289,115), Brazil (19,474,489), Russia (6,030,240), and the
53	France (5,911,601) on 22 July 2021. Every country in South Asia is affected by this zoonotic
54	virus. About 31,289,115 cases in India have been identified, one of the top five affected
55	countries (Worldometers, n.d.). Bangladesh announced the first confirmed coronavirus cases on
56	8 March 2020, and this number increased day by day (Anwar et al., 2020). It was reported that
57	about 1,136,503 cases were identified, 18.498 patients died, and 961,044 patients are recovered
58	by 22 July 2021 (Worldometers, n.d.). It is now spreading all over the country, and the highest
59	affected area was observed in the Dhaka division. Based on district-wise case distribution,
60	around 5546 and 2309 patients were identified, and 5058 and 2232 patients were recovered in
61	Noakhali and Lakshmipur, respectively, on 31 December 2020 (Civil Surgeon Office, Noakhali,
62	and Laxmipur, 2020, Corona Information, n.d.). It diffuses via people-to-people transmission, for
63	instance, sneezing and coughing, while some research indicates the transmission chances even
64	amongst the asymptomatic (Ningthoujam, 2020). It can also spread through stool, sweat, urine,
65	and respiratory secretions.
66	
67	The general incubation period of this virus is 1 to 14 days (Read at al. 2020); however, a longer

The general incubation period of this virus is 1 to 14 days (Baud et al., 2020); however, a longer
latent period has been reported in some cases, which makes it more dangerous as the host may
transmit the disease to others unknowingly (Kong, 2020). The most frequently occurring

70	symptoms are fever, cough, sore throat, tiredness, ache, headache, etc. Still, severe illnesses,
71	including- diarrhea, pneumonia, pulmonary edema, acute respiratory distress syndrome, multiple
72	organ failure, are also found among patients (Chen et al., 2020; Y. Meng et al., 2020). Both
73	males and females are affected by COVID-19, but several epidemiological and clinical studies
74	suggest that males are more progressive to infection than females (Barek et al., 2020; Y. Meng et
75	al., 2020). Many studies have already found that single or multiple comorbidities like high blood
76	pressure, cardiovascular disease, high blood pressure, liver problem, diabetes, lung disease, and
77	kidney disease patients are more affected by this virus (Barek et al., 2020; Emami et al., 2020).
78	Researchers are trying to develop medicine and vaccine to combat COVID-19 and upcoming
79	SARS and MERS viruses (Amanat and Krammer, 2020). Now, public concern and
80	consciousness are the main prohibitions for the COVID-19 outbreak.
81	
82	At present, epidemiological, clinical characteristics, the pervasiveness of comorbidities, other
83	information is most important to take necessary steps for treatment, prevention, and control of
84	the current outbreak. There have no published demographic and clinical characteristics study
85	data regarding COVID-19 patients of Bangladesh. Considering the above-mentioned facts, we
86	analyzed 385 laboratory-confirmed COVID-19 positive patients' demographic data, clinical
87	manifestations, medical history, blood group, travel history, previous vaccination, and other data
88	from the southeast region in Bangladesh for the very first time, which help to proper decisions to
89	reduce the risk of infection.
90	

- 91
- 92

93 2 Methods

94 2.1 Study design and participants

We selected only laboratory-confirmed Covid-19 cases between 5 June 2020 to 10 September 95 96 2020 who were tested at Noakhali Science and Technology University COVID-19 testing 97 laboratory, Noakhali, Bangladesh approved by the government (The Daily Star, 2020). The 98 specimen was collected by nasopharyngeal swab, and reverse transcriptase-polymerase chain reaction (RT-PCR) assay was used for Covid-19 confirmation. Three hundred eighty-five 99 100 patients (aged above 5 years) were identified as positive from the southeast region, Bangladesh 101 (Noakhali and Lakshmipur) in where 286 patients were male and 99 were female. Pregnant women, children, adults, and older patients were included in this study. To avoid the chance of 102 bias, participants were selected and listed with the help of the Noakhali Science and Technology 103 University Covid-19 testing laboratory database. 104

105

106 2.2 Data collection

The questionnaire was adopted from formerly published studies, and our research team added, 107 modified, and developed some questions. There were various sections in the survey, including 108 demographic information, clinical characteristics, pre-existing medical condition, blood group, 109 earlier visited information, vaccination, etc. The investigators were told that their participation 110 111 was anonymous and entirely voluntary, and there was no reward for taking part. All the participants willingly participated in this work by giving written permission. They were invited 112 to complete the questionnaire. We were present on hand to answer questions or clarify any 113 doubts that they might have. All filled questionnaires were collected by us one by one. 114

115

116 2.3 Definition

117	Patients with SARS-CoV-2 infection have no clinical signs and symptoms were defined as
118	asymptomatic cases, and symptomatic patients were defined with SARS-CoV-2 infection
119	presenting with clinical characteristics from medical interviews. Comorbidities were ascertained
120	from physician documentation.
121	
122	2.4 Specimen collection and RT-PCR assay for SARS-CoV-2
123	We detected the presence of SARS-CoV-2 by the qPCR method with the novel coronavirus
124	(2019-nCoV) nucleic acid diagnostic Kit (PCR-fluorescence probing). The test utilizes the novel
125	coronavirus (2019-nCoV) ORF 1ab and the specific conserved sequence of coding nucleocapsid
126	protein N gene as the target regions to detect sample RNA through fluorescence signal changes.
127	These diagnostic criteria were based on the recommendations by the Institute of Epidemiology,
128	Disease Control and Research (IEDCR), Bangladesh. Test facility and quality reconfirmed by
129	IEDCR.

130

131 2.5 Statistical Analysis

132 Descriptive statistics were used to summarize the data, continuous variables were expressed as 133 mean \pm SD, and categorical variables were summarized as counts and percentages. There are 134 several kinds of models for analyzing the relationship between the data sets. As our data are 135 parametric, we used Pearson's Correlation Coefficient (2-tailed). All statistical analysis was 136 conducted using the IBM Statistical Package for the Social Sciences (SPSS), version 25.0 137 software. P < 0.05 was considered statistically significant. Correlation between sex and many 138 other factors i.e. BMI, age, comorbidities, etc., was analyzed and determined.

3 Results 139

140	The demographic characteristics of all the confirmed COVID-19 cases (N=385) were shown in
141	Table 1. Of them, 74.3% of cases were male, and 25.7% were female, with an average age of
142	34.86 ± 15.442 years. The highest number of patients was in the age range of 21-50 years
143	(71.91%). However, around 15% of cases were found older than them. As for Body Mass Index
144	(BMI), 23.80% of cases were overweight, and 8.10% were obese, while only 3.40% were
145	underweight. A (+ve), B (+ve), and O (+ve) blood groups were the most identified blood group
146	with a percentage of 25.46%, 32.52%, and 18.40%, respectively. In the meanwhile, only a few
147	percent of patient cases were observed with O (-ve) (3.07%), B (-ve) (3.68%), and A (-ve)
148	(3.37%) blood group. Of the male with a positive blood group, the most common blood group
149	was B (+ve) (35.22%), followed by A (+ve) (22.76%) and AB (+ve) (16.46%). In the female
150	positive blood group, the most specific blood group was still B (+ve) and O (+ve) (24.05%) in
151	each case, followed by A (+ve) (21.05%) and AB+ (15.79%) (Figure 1).
152	

About 28.50% of cases passed the higher secondary certificate (HSC) level, while only 9.40% 153 continued their education until the secondary school certificate (SSC) level. Graduated (25.50%) 154 and post graduated (11.75%) cases were also observed in our study. Notably, most of the 155 COVID-19 patients were businessmen (18.80%), students (15.43%), civil servants (14.09%), and 156 health workers (8.05%). In male cases, 23.04% were businessmen, followed by 17.83% civil 157 servants and 8.26% health workers. However, two-thirds of the female cases (61.76%) were 158 159 housewives, followed by 20.59% of students (Figure 2). All confirmed cases ensured that they did not travel to any other countries within the nearest time before being infected. However, 160 most of them visited their workplace (65.95%), local market (45.39%), and health care center 161

162	(13.80%) within the earlier time. About 19.63% and 18.09% of cases visited the bank and
163	relative house, respectively. Our study also explored that only 15.50% of infected persons had
164	clear contact with confirmed cases as far as they know. Additionally, diabetes (5.19%),
165	hypertension (5.97%), asthma (7.53%), allergy (0.52%) cancer (0.78%), pregnancy (2.34%) and
166	others (1.29%) were the most common comorbidities identified among the confirmed cases.
167	Most of the patients were vaccinated with BCG (86.2%), Polio (87.9%), Mumps (54%), Tetanus
168	(82.5%). However, only a few of them were vaccinated with Hepatitis B (14.8%), Chickenpox
169	(15.1%), and Measles (3%).
170	
171	Analysis of demographic characteristics based on gender-specific is explored in Table 2. This
172	analysis showed that BMI and earlier visited places showed significant ($p < 0.05$) differences
173	between male and female patients. The highest percent of both males (74.24%) and females
174	(68.1%) were in the age range of 21-50 years. About 88.66% male cases and 92.40% female
175	cases had positive Rh factor ($p = 0.115$). Additionally, earlier visited place such as workplace (p
176	< 0.001), bank ($p < 0.001$), local market ($p < 0.001$), and social gathering ($p < 0.001$) were also
177	reported as the significant risk factors for sex-specific COVID-19 infection. Among all
178	comorbidities, our study found significant differences between males and females in the case of
179	only chickenpox ($p = 0.014$).
180	
181	Signs and symptoms identified during testing among COVID-19 confirmed cases are tabulated in
182	Table 3. Our study also confirmed the sex-specific clinical characteristics of COVID-19. This
183	present study found that less than half of the confirmed COVID-19 cases (37.73%) were

symptomatic, and this asymptomatic characteristic was more prevalent among females (40.51%)

185	than that of males (36.84%) patients ($p = 0.001$). Conversely, mortality cases were found higher
186	for males than females with no significant correlation ($p = 0.724$). Of the patients showing
187	symptoms, the most frequent symptom was fever (29.45%), followed by cough (34.05%) and
188	headache (13.50%), with no significant difference between genders. Fever and cough were
189	observed mainly among females (55.32% and 44.87%) than male patients (44.87% and 53.85%).
190	Also, 8.28% of cases and 13.50% of cases experienced sore throat and headache. Though very
191	few female cases showed fever ($p = 0.240$); however, about 37.82% of male cases experienced
192	sore throat in comparison to only 25.53% of female cases ($p = 0.204$).
193	

4 Discussion 194

The new beta coronavirus is the third type of zoonotic coronavirus, the seventh human 195 coronavirus, and has similarities with previous coronavirus (Zhou et al., 2020; Zhu et al., 2020). 196 197 This contagious virus shows the same receptor binding domain with SARS coronavirus (SARS-CoV) and MERS-CoV (Lu et al., 2020). The number of COVID-19 cases continuously rising 198 worldwide, but no specific treatment has been confirmed to be fully effective against COVID-19 199 (irrespective of different strains). Therefore, it is crucial to identify the clinical demographical 200 characteristics, clinical manifestation, comorbidities, and other information of COVID-19 201 202 patients. It is also important to help in the early detection and isolation of infected individuals and minimize the spread of the disease, severity, and death rate. To our best knowledge, this is 203 the first study undertaken to investigate the demographic, clinical characteristics, comorbidities, 204 205 and excrescent information of the confirmed COVID-19 patients from the southeast region in Bangladesh. 206

207

We analyzed 200 positive samples from Noakhali and 185 positive samples from Lakshmipur, 208 209 the southeast region of Bangladesh. In our study, we observed that the number of male patients was largely (74.3%), almost three times higher than female patients (25.7%). Several studies 210 conducted in China and other countries corroborated a higher number of infected males than that 211 of females (Novel, 2020; Z. Wang et al., 2020). Meanwhile, a research study by Zhou et al. 212 213 suggests that the expression of ACE2, the receptor for COVID-19, is higher in males than that in females, which may be the reason behind the higher proportion of COVID-19 infected males 214 215 (Zhou et al., 2020). It is also thought that as females have more X chromosomes and sex 216 hormones, these factors play an essential role in innate and adaptive immunity (Jaillon et al., 2019). On the other hand, Females are less associated with a bad lifestyle than males. Similarly, 217 several studies found that males are more infected than females during MERS-CoV and SARS-218 CoV pandemic (Badawi and Ryoo, 2016; Channappanavar et al., 2017). Additionally, the 219 average age of all cases was 34.86 ± 15.442 years old and nearly similar to several studies 220 221 (Azlan et al., 2020; Q. Huang et al., 2020; Kim et al., 2020). It might be due to the outgoing of middle-aged people for their respective work or for their family need as they have to meet all 222 family and society demands. However, our study indicated that patients at a wide age range can 223 224 be infected by SARS-CoV-2. This present study also demonstrated a slightly greater mean BMI 225 value than those found in the Hubei (Yang et al., 2020) and Jiangsu (R. Huang et al., 2020) 226 provinces of China. Notably, more than three fourth of patients involved in our study had a 227 positive blood group, including A (+ve) (25.46%), B (+ve) (32.52%), and O (+ve) (18.40%), similar to Li et al. and Zietz et al. studies (Li et al., 2020; Zietz et al., 2020). According to one 228 229 study, anti-A antibodies inhibit S protein/angiotensin-converting enzyme 2-dependent adhesion 230 of these cells to an angiotensin-converting enzyme 2 expressing cell line (Guillon et al., 2008).

232	Besides, the majority of infected cases were business professionals (18.80%), followed by
233	students (15.43%), civil servants (14.09%), and health workers (8.05%), which is more in this
234	study (Azlan et al., 2020; L. Wang et al., 2020). Consistent with the previous study conducted in
235	Wuhan (D. Wang et al., 2020), this present study also explored males who are mainly visited in
236	the workplace (82.97%, $p < 0.001$) and local market (58.08%, $p < 0.001$). Conversely, males
237	need to attend their daily work for livelihood and go to the local market for their daily needs.
238	Besides, both males (12.66%) and females (16.49%) are early visited in the health care center.
239	Noticeably, no patients had travelled to any other country within the nearest time before getting
240	infected, and only 15% of cases reported the known contact with confirmed cases. Of the
241	confirmed cases, the other frequently observed comorbidities were hypertension (male vs.
242	female: 7.29% vs. 2.06%, $p = 0.060$), diabetes mellitus (male vs. female: 4.86% vs. 6.18%, $p = 0.060$)
243	0.612), asthma (male vs. female: 8.33% vs. 5.15%, $p = 0.306$), cancer (male vs. female: 0.01%)
244	vs. 1.00%, $p = 0.745$) and pregnancy (female: 5.26%, $p < 0.001$). However, they were observed
245	with a lower percentage than the preceding observation in China and Italy (Colaneri et al., 2020;
246	R. Huang et al., 2020; H. Meng et al., 2020). Maximum patients take necessary vaccines such as
247	Polio (87.9%), BCG (86.2%), Tetanus (82.5%), Mumps (54%) were taken in life. About 37.73%
248	of cases were asymptomatic confirmed COVID-19 cases in the southeast region ($p = 0.001$).
249	Only 5% of asymptomatic cases were observed in Beijing (Tian et al., 2020), and this
250	asymptomatic characteristic was more prevalent among females (40.51%) than that of male
251	(36.84%) patients ($p = 0.001$), which is similar to our findings. We recorded all the identified
252	signs and symptoms of the symptomatic cases. Out of these, the most dominant symptom was
253	cough (34.05%), followed by fever (29.45%). Other symptoms of fatigue (21.78%), headache

(13.50%), sore throat (8.28%), ache (12.58%), and diarrhea (3.07%) were also found among 254 patients. In the meanwhile, several studies conducted in Wuhan (Y. Meng et al., 2020), Shanghai 255 (Yu et al., 2020), Beijing (Niu et al., 2020), Hubei (Yang et al., 2020), Jiangsu (R. Huang et al., 256 2020), and United States (Aggarwal et al., 2020) found that fever and cough as dominant clinical 257 symptoms. However, 29.45% of our study's symptomatic patients showed comparatively higher 258 259 fever than that in South Korea (11.6%) (Kim et al., 2020). 260 261 There have been no published studies on sex-specific demographics, clinical characteristics, and 262 comorbidity of COVID-19 infected patients, Bangladesh. This work is the first cross-sectional study and the most comprehensive assessment and robust evidence of patients clinical 263

characteristics and comorbidities with COVID-19. Albeit this is a novel study, several limitations 264 might be noted in the present study. Firstly, the present study was performed only in a single 265 266 institution by obtaining data when patients came for coronavirus testing. Hence, the represented data does not give the whole scenario of all COVID-19 patients of the country. Secondly, the 267 limited number of study populations, especially for female patients. Finally, we did not include 268 269 any data from hospitalized patients and laboratory outputs. Further investigations are required by the use of enormous raw data and secondary COVID-19 data in the study. However, our study 270 analyzed the demographic and clinical characteristics of COVID-19 patents that aid in 271 identifying possible risk factors and reducing the risk of COVID-19 susceptibility to control this 272 outbreak. 273

274

275 **5** Conclusions

Nowadays, COVID-19 is a contagious disease and led to a major global health concern. Due to 276 277 the dynamic nature of the pandemic, more and continuous epidemiological models are needed for forecasting and preparedness in different scenarios. In the present study, we found that males 278 were more affected than female patients, and middle-aged people were mainly affected in both 279 sexes. Fever, cough, and tiredness were the common symptoms found among patients, and 280 281 several comorbidities (diabetes, hypertension, and asthma) were present among patients. Maximum COVID-19 patents were B (+ve), and businessmen were mostly affected by this 282 infectious virus. We also observed that the coronavirus mainly affected male patients due to the 283 earlier visit to the workplace, local market, and bank. As the epidemic situation in Bangladesh 284 worsens by the day, reinforcing all of the country's mitigation measures and laws, as well as 285 adhering to all WHO guidelines, is critical at this time to maintain the exposure probability and 286 transmission rate as low as possible. We anticipate this study will raise the knowledge about 287 COVID-19 and help to take effective and proper decisions to identify risk factors to control this 288 289 pandemic.

290

291 Funding disclosure

This work was supported by the Research Cell, Noakhali Science and Technology University,Bangladesh.

294

295 Ethical approval

The study protocol was approved by the institutional ethical clearance committee of Noakhali
Science and Technology University, Bangladesh (Approval ID: 44-2020).

298

299 Acknowledgments

300 We acknowledge the sincere help extended by several COVID-19 Diagnostic Lab Volunteers to

301 name a few are: Md. Sahedul Islam, Md. Amzad Hossain, Mahmudul Islam Rakib, Golam

- 302 Shamdani, Amor Chandra Nath, and Md. Julker Nyne, of Noakhali Science and Technology
- 303 University, Bangladesh.
- 304

305 **References**

- 306 Aggarwal S, Garcia-Telles N, Aggarwal G, Lavie C, Lippi G, Henry BM. Clinical features,
- 307 laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019
- 308 (COVID-19): Early report from the United States. Diagnosis 2020;7:91–6.
- Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity 2020;52:583–9.
- 310 https://doi.org/10.1016/j.immuni.2020.03.007.
- Anwar S, Nasrullah M, Hosen MJ. COVID-19 and Bangladesh: Challenges and How to Address
- 312 Them. Front Public Heal 2020;8:154. https://doi.org/10.3389/fpubh.2020.00154.
- Azlan AA, Hamzah MR, Sern TJ, Ayub SH, Mohamad E. Public knowledge, attitudes and
- practices towards COVID-19: A cross-sectional study in Malaysia. PLoS One 2020;15.
- 315 https://doi.org/10.1371/journal.pone.0233668.
- Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome
- coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis 2016;49:129–
 33.
- 319 Barek MA, Aziz MA, Islam MS. Impact of age, sex, comorbidities and clinical symptoms on the
- severity of COVID-19 cases: A meta-analysis with 55 studies and 10014 cases. Heliyon
- 321 2020;6:e05684. https://doi.org/10.1016/j.heliyon.2020.e05684.
- Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality
- following COVID-19 infection. Lancet Infect Dis 2020.
- 324 Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia
- associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of
- a family cluster. Lancet 2020;395:514–23.
- 327 Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-based
- 328 differences in susceptibility to severe acute respiratory syndrome coronavirus infection. J
- 329 Immunol 2017;198:4046–53.


- 330 Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical
- characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive
- study. Lancet 2020;395:507–13.
- 333 Civil Surgeon Office, Noakhali, and Laxmipur. 2020.
- 334 Colaneri M, Sacchi P, Zuccaro V, Biscarini S, Sachs M, Roda S, et al. Clinical characteristics of
- coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21
- to 28 February 2020. Eurosurveillance 2020;25. https://doi.org/10.2807/1560-
- 337 7917.ES.2020.25.16.2000460.
- 338 Corona Information. Corona News n.d. https://corona.gov.bd/corona-news.
- 339 Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases in
- 340 Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. Arch Acad
- 341 Emerg Med 2020;8:e35. https://doi.org/10.22037/aaem.v8i1.600.
- 342 Guillon P, Clément M, Sébille V, Rivain JG, Chou CF, Ruvoën-Clouet N, et al. Inhibition of the
- interaction between the SARS-CoV Spike protein and its cellular receptor by anti-histo-blood
- group antibodies. Glycobiology 2008;18:1085–93. https://doi.org/10.1093/glycob/cwn093.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with
- 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
- 347 https://doi.org/10.1016/S0140-6736(20)30183-5.
- Huang Q, Deng X, Li Y, Sun X, Chen Q, Xie M, et al. Clinical characteristics and drug therapies
- in patients with the common-type coronavirus disease 2019 in Hunan, China. Int J Clin Pharm2020:1.
- Huang R, Zhu L, Xue L, Liu L, Yan X, Wang J, et al. Clinical findings of patients with
- 352 coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study. PLoS
- 353 Negl Trop Dis 2020;14:e0008280.
- Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. Clin Rev Allergy
 Immunol 2019:1–14.
- 356 Kim GU, Kim MJ, Ra SH, Lee J, Bae S, Jung J, et al. Clinical characteristics of asymptomatic


- and symptomatic patients with mild COVID-19. Clin Microbiol Infect 2020;26:948.e1-948.e3.
- 358 https://doi.org/10.1016/j.cmi.2020.04.040.
- Kong T. Longer incubation period of coronavirus disease 2019 (COVID-19) in older adults.
- 360 AGING Med 2020;3:102–9. https://doi.org/10.1002/agm2.12114.
- 361 Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome
- 362 coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the
- 363 challenges. Int J Antimicrob Agents 2020:105924.
- Li J, Wang X, Chen J, Cai Y, Deng A, Yang M. Association between ABO blood groups and
- risk of SARS-CoV-2 pneumonia. Br J Haematol 2020;190:24–7.
- 366 https://doi.org/10.1111/bjh.16797.
- Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends
 2020;14:69–71.
- 369 Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterization and epidemiology of
- 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet
 2020:395:565–74.
- 372 Meng H, Xiong R, He R, Lin W, Hao B, Zhang L, et al. CT imaging and clinical course of
- asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China. J Infect
- 374 2020;81:e33–9. https://doi.org/10.1016/j.jinf.2020.04.004.
- 375 Meng Y, Wu P, Lu W, Liu K, Ma K, Huang L, et al. Sex-specific clinical characteristics and
- prognosis of coronavirus disease-19 infection in Wuhan, China: A retrospective study of 168
- severe patients. PLoS Pathog 2020;16:e1008520.
- Ningthoujam R. COVID 19 can spread through breathing, talking, study estimates. Curr Med
- 379 Res Pract 2020;10:132–3. https://doi.org/10.1016/j.cmrp.2020.05.003.
- 380 Niu S, Tian S, Lou J, Kang X, Zhang L, Lian H, et al. Clinical characteristics of older patients
- infected with COVID-19: A descriptive study. Arch Gerontol Geriatr 2020;89.
- 382 https://doi.org/10.1016/j.archger.2020.104058.
- 383 Novel CPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus

- diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi= Zhonghua
- Liuxingbingxue Zazhi 2020;41:145.
- 386 The Daily Star. Coronavirus Test Lab Ina Noakhali Sci Technol Univ 2020.
- 387 Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in
- 388 Beijing. J Infect 2020;80:401–6. https://doi.org/10.1016/j.jinf.2020.02.018.
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized
- 390 patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama
- **391** 2020;323:1061–9.
- Wang L, Duan Y, Zhang W, Liang J, Xu J, Zhang Y, et al. Epidemiologic and clinical
- 393 characteristics of 26 cases of COVID-19 arising from patient-to-patient transmission in
- Liaocheng, China. Clin Epidemiol 2020;12:387.
- 395 Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for
- four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western
- 397 medicine treatment. Biosci Trends 2020.
- 398 Worldometers. Confirmed Cases Deaths by Country, Territ or Convey n.d.
- 399 https://www.worldometers.info/coronavirus/.
- 400 Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al. Clinical characteristics, outcomes,
- 401 and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a
- 402 multicentre, retrospective, cohort study. Lancet Oncol 2020.
- Yu X, Sun X, Cui P, Pan H, Lin S, Han R, et al. Epidemiological and clinical characteristics of
 333 confirmed cases with coronavirus disease 2019 in Shanghai, China. Transbound Emerg Dis
 2020.
- Zheng J. SARS-CoV-2: an emerging coronavirus that causes a global threat. Int J Biol Sci2020;16:1678.
- 408 Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak
- 409 associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3.
- 410 Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with

- 411 pneumonia in China, 2019. N Engl J Med 2020.
- 412 Zietz M, Zucker J, Tatonetti NP. Associations between blood type and COVID-19 infection,
- 413 intubation, and death. Nat Commun 2020;11:1–6.

Figures





424 Tables

425 Table 1: Demographic characteristics of COVID-19 cases from the southeast region in

426 Bangladesh

Response	Patients
Male	286 (74.3%)
Female	99 (25.7%)
Mean \pm SD	34.86 ± 15.442
0-20	50(13.12%)
21-50	274 (71.91%)
>51	57 (14.96%)
Mean \pm SD	24.1012 ± 4.117
<18.5 (Underweight)	10 (3.40%)
	193 (64.7%)
25-29.9 (Overweight)	71 (23.80%)
	24 (8.10%)
× /	× /
A (+ve)	83(25.46%)
	106 (32.52%)
	43 (13.19%)
	60 (18.40%)
	11 (3.37%)
	12 (3.68%)
	1 (0.31%)
	10 (3.07%)
Masters	35 (11.75%)
Graduate	76 (25.50%)
Degree	8 (2.68%)
-	85 (28.50%)
SSC	28 (9.40%)
Below SSC	46 (15.44%)
	20 (6.73%)
Civil servant Health worker (doctor, nurse, sample collector) Engineer Banker	42 (14.09%) 24 [7,8,9] (8.05%) [2.68%,2.35%,3.02%] 1 (0.33%) 8 (2.68%)
	MaleFemaleMean \pm SD0-2021-50>51Mean \pm SD<18.5 (Underweight)

	Businessmen	56 (18.80%)
	Homemaker	42 (14.09%)
	Student	46 (15.43%)
	Others	36 (12.08%)
Traveling to other countries (N=298)		
	Yes	6 (2.01%)
	No	292 (97.99%)
Earlier visited places (N=326)		
	Workplace	215 (65.95%)
	Bank	64 (19.63%)
	Local market	148 (45.39%)
	Relatives house	59 (18.09%)
	Social gathering	36 (11.04%)
	Health care center	45 (13.80%)
Comorbidities (N= 385)		× ,
	Diabetes	20 (5.19%)
	Hypertension	23 (5.97%)
	Asthma	29(7.53%)
	Allergy	2(0.52%)
	Cancer	3(0.78%)
	Pregnancy	9 (2.34%)
	Others	5 (1.29%)
	No risk factors	296 (76.35%)
Vaccine in life (N=298)		()
· · · · · ·	BCG	257 (86.2%)
	Polio	262 (87.9%)
	Hepatitis B	44 (14.8%)
	Mumps	161 (54.00%)
	Tetanus	246 (82.5%)
	Chickenpox	45 (15.1%)
	Measles	9 (3.00%)
Death Case		× ,
Age (years) (N=130)	Mean \pm SD	62.56 ± 14.252
Age group	0-20	1 (0.77%)
	21-50	23 (17.70%)
	>51	106 (81.54%)

427

Category	Male	Female	<i>p</i> -value
Age group (Years) (M=284, F= 97	7)		
0-20	30 (10.56%)	20 (20.6%)	
21-50	208 (73.24%)	66 (68.1%)	0.275
>51	46 (16.20%)	11 (11.3%)	
BMI range (M=230, F= 68)			
<18.5 (Underweight)	6 (2.61%)	4 (5.9%)	
18.5-24.9 (Normal)	152 (66.09%)	41 (60.29%)	< 0.001*
25-29.9 (Overweight)	52 (22.60%)	19 (27.94%)	< 0.001*
>30 (Obese)	17 (8.70%)	4 (5.88%)	
Rh factor (M=247, F=79)			
Positive	219 (88.66%)	73 (92.40%)	0 1 1 5
Negative	28 (11.34%)	6 (7.60%)	0.115
Traveling to other countries			
(M=230, F=68)			
Yes	5 (2.17%)	1 (1.47%)	0.760
No	225 (97.83%)	67 (98.53%)	0.769
Earlier visited places			
(M=229, F=97)			
Workplace	190 (82.97%)	25 (25.77%)	< 0.001*
Bank	55 (24.01%)	9 (9.28%)	< 0.001*
Local market	133 (58.08%)	15 (15.46%)	< 0.001*
Relatives house	38 (16.60%)	21 (21.65%)	0.404
Social gathering	34 (14.85%)	2 (2.06%)	< 0.001*
Health care center	29 (12.66%)	16 (16.49%)	0.400
Comorbidities (M= 288, F=97)			
Diabetes	14 (4.86%)	6 (6.18%)	0.612
Hypertension	21 (7.29%)	2 (2.06%)	0.060

429 Table 2: Sex-specific analysis of demographic characteristics of confirmed COVID-19 cases

Asthma	24 (8.33%)	5 (5.15%)	0.306
Cancer	2 (0.01%)	1 (1.00%)	0.745
Pregnancy		9 (9.27%)	< 0.001*
Others	3 (1.04%)	2 (2.06%)	0.444
No risk factors	224 (77.78%)	72 (74.22%)	
Vaccine in life (M=230, F=68)			
BCG	81 (100.00%)	55 (80.9%)	0.084
Polio	81 (100.00%)	59 (86.8%)	0.519
Hepatitis B	12 (14.81%)	14 (20.6%)	0.159
Mumps	77 (95.06%)	40 (58.8%)	0.551
Tetanus	75 (92.59%)	54 (79.4%)	0.318
Chickenpox	1 (1.23%)	17 (25.00%)	0.014**
Measles	7 (3.04%)	2 (2.94%)	0.928
Diphtheria	196 (85.22%)	55(80.9%)	0.269

430

^{*} Correlation is significant at the 0.01 level (2-tailed)

^{**} Correlation is significant at the 0.05 level (2-tailed)

Items	Total (%)	Male (%)	Female (%)	<i>p</i> -value
Asymptomatic	123 (37.73%)	91 (36.84%)	32 (40.51%)	0.001*
Symptomatic	203 (62.27%)	156 (63.16%)	47 (59.49%)	
Symptoms				
(M=156, F=47)				
Fever	96 (29.45%)	70 (44.87%)	26 (55.32%)	0.240
Cough	111 (34.05%)	84 (53.85%)	27 (57.45%)	0.666
Sore throat	27 (8.28%)	22 (14.10%)	5 (10.64%)	0.542
Headache	44 (13.50%)	34 (21.79%)	10 (21.27%)	0.817
Tiredness	71 (21.78%)	59 (37.82%)	12 (25.53%)	0.204
Ache	41 (12.58%)	28 (17.95%)	13 (27.66%)	0.080
Diarrhea	10 (3.07%)	7 (4.48%)	3 (6.38%)	0.601
Death significance (M=108, F=22)				
Age (years)				
0-20	1 (0.77%)	1 (0.93%)	0 (0.00%)	
21-50	23 (17.70%)	17 (15.70%)	6 (27.27%)	0.724
>50	1 (0.77%)	90 (83.33%)	16 (72.72%)	

Table 3: Sex-specific signs and symptoms of COVID-19 patients identified during testing

^{*}*Correlation is significant at the 0.01 level (2-tailed)*